Key Takeaways TEVA beat Q2 earnings estimates with $0.66 per share, though revenues of$4.18B missed expectations.Branded drugs Ajovy, Austedo, and Uzedy drove U.S. sales, offsetting declines in generics and Copaxone.TEVA reaffirmed 2025 revenue guidance and raised sales outlook for Ajovy, Austedo, and Uzedy.Teva Pharmaceutical Industries (TEVA) reported second-quarter 2025 adjusted earnings of 66 cents per share, which beat the Zacks Consensus Estimate of 63 cents. Adjusted earnings rose 8% year over year, ...